Page last updated: 2024-09-04

abiraterone and Disease Exacerbation

abiraterone has been researched along with Disease Exacerbation in 96 studies

Research

Studies (96)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	5 (5.21)	29.6817
2010's	81 (84.38)	24.3611
2020's	10 (10.42)	2.80

Authors

Authors	Studies
Ai, J; Bai, S; Lei, H; Liao, D; Peng, G; Qiu, S; Wei, Q; Xiong, X; Xu, H; Yang, L; Yi, X	1
Abida, W; Bambury, RM; Bryce, AH; Chowdhury, S; Daugaard, G; Despain, D; Emmenegger, U; Fizazi, K; Gingerich, JR; Heidenreich, A; Heyes, CA; Krieger, L; Lindberg, H; Loehr, A; McDermott, R; Morris, D; Nolè, F; Ostler, P; Pintus, E; Piulats, JM; Reaume, MN; Redfern, C; Ryan, CJ; Sáez, MI; Sautois, B; Sridhar, SS; Staffurth, J; Watkins, SP	1
Autorino, R; Castellan, P; Cindolo, L; Di Nicola, M; Marchioni, M; Novara, G; Paul, AK; Primiceri, G; Schips, L; Veccia, A	1
Aschelter, AM; De Sanctis, V; Macrini, S; Marchetti, P; Marinelli, L; Osti, MF; Reverberi, C; Tronnolone, L; Valeriani, M	1
Barata, PC; Chapman, L; Christensen, BR; Cotogno, P; Layton, JL; Ledet, EM; Lewis, BE; Manogue, C; Moses, M; Ranasinghe, L; Sartor, O; Steinwald, P	1
Ardizzoni, A; Battelli, N; Conti, A; Di Nunno, V; Massari, F; Mollica, V; Montironi, R; Santoni, M	1
Briganti, A; Egawa, S; Karakiewicz, PI; Kimura, S; Kimura, T; Miura, N; Mori, K; Mostafaei, H; Pradere, B; Quhal, F; Sari Motlagh, R; Shariat, SF	1
Ahmed, ME; Alamiri, J; Alom, M; Andrews, JR; Haloi, R; Higa, J; Jeffrey Karnes, R; Joshi, V; Kwon, E; Motterle, G; Shah, PH	1
Bourlon, C; Bourlon, MT; Carretero-Gonzalez, A; Carril-Ajuria, L; Castellano, D; de Velasco, G; Martin-Soberon, M; Remolina-Bonilla, YA	1
Afonso, A; Carneiro, F; Coelho, S; Lopes, AR; Maurício, MJ; Medeiros, R; Patrão, AS; Pinto, AR; Rosinha, A; Silva, J	1
Gotoh, M; Hattori, K; Hattori, R; Ishikawa, T; Kato, M; Kawanishi, H; Kimura, T; Matsukawa, Y; Naito, Y; Nishikimi, T; Sano, T; Tsuzuki, T; Yamamoto, A; Yuba, T; Yuguchi, Y	1
Dineen, M; Guancial, E; Hansen, E; Sahasrabudhe, D; Sievert, L	1
Akamatsu, S; Antonarakis, ES; Inoue, T; Kamba, T; Kobayashi, T; Maughan, BL; Ogawa, O; Terada, N; Yamasaki, T	1
Amadori, D; Attard, G; Casadio, V; Castellano, D; Climent, MA; Conteduca, V; De Giorgi, U; Dearnaley, D; Demichelis, F; Duran, I; Fernandez-Calvo, O; Fernandez-Perez, MP; Font, A; Gallardo, E; Gasi Tandefelt, D; González Del Alba, A; Gonzalez-Billalabeitia, E; Grande, E; Gurioli, G; Jayaram, A; Lolli, C; Mellado, B; Méndez-Vidal, MJ; Puente, J; Rodriguez, A; Romanel, A; Sáez, MI; Salvi, S; Santander, C; Sharabiani, MTA; Vazquez-Estevez, S; Wetterskog, D; Wingate, A	1
Egawa, S; Kimura, S; Kimura, T; Miki, J; Miki, K; Mori, K; Onuma, H; Sasaki, H; Yamamoto, T	1
Bianchini, D; de Bono, J; Gilman, A; Hall, E; IJzerman, M; Kolinsky, M; Lorente, D; Mateo, J; Mehra, N; Miranda, M; Omlin, A; Payne, H; Perez, R; Pezaro, C; Porta, N; Ravi, P; Rescigno, P; Terstappen, L; Tunariu, N	1
Enokida, H; Inoue, S; Ishibashi, K; Izumi, K; Kamiyama, M; Kawai, N; Mizokami, A; Namiki, M; Shima, T; Takahara, S; Tanaka, N; Yoshio, Y	1
Brown, JS; Cunningham, JJ; Gatenby, RA; Zhang, J	1
Hao, S; He, Y; Huang, H; Kohli, M; Li, B; Lu, J; Tindall, DJ; Wang, L; Ye, Z; Zhu, R	1
Buelens, S; Claeys, T; Dhondt, B; Kumps, C; Lumen, N; Ost, P; Poelaert, F; Thas, O; Vandesompele, J; Vynck, M; Yigit, N	1
Bianchini, D; Crespo, M; de Bono, JS; Dolling, D; Figueiredo, I; Flohr, P; Lorente, D; Mateo, J; Miranda, S; Olmos, D; Scher, HI; Seed, G; Terstappen, LWMM	1
Buzza, M; Casey, O; Catto, J; Chan, JM; Courneya, KS; Finn, SP; Galvão, DA; Gledhill, S; Greenwood, R; Guinan, EM; Hart, NH; Hughes, DC; Kenfield, SA; Mucci, L; Newton, RU; Plymate, SR; Praet, SFE; Ryan, CJ; Saad, F; Van Blarigan, EL; Zhang, L	1
Ali, R; Chambers, C; Ghosh, S; North, S; Sawyer, M; Shivji, A	1
Barret, E; Bennamoun, M; Bonnetain, F; Cathala, N; Cathelineau, X; Charton, E; Fenioux, C; Henriques, J; Joulia, ML; Louvet, C; Molitor, JL; Mombet, A; Prapotnich, D; Ropert, S; Rozet, F; Sanchez-Salas, R	1
Attard, G; Castro, E; Cendón, Y; Correa, R; Cruz, JJ; Garcés, T; Grau, G; Gutierrez-Pecharoman, A; Herrera, B; Jayaram, A; López, PP; López-Campos, F; Lorente, D; Lozano, R; Montesa, A; Nombela, MP; Olmos, D; Pacheco, MI; Rivera, L; Romero-Laorden, N; Rosero, A; Saez, MI; Van de Poll, F; Villatoro, R	1
Alva, AS; Cao, X; Chinnaiyan, AM; Delekta, A; Jing, X; Juckette, KM; Kim, Y; Luo, E; MacLeod, AR; Parolia, A; Qiao, Y; Shukla, S; Su, F; Tan, M; Tien, JC; Vo, J; Wang, L; Wang, X; Xiao, L; Xu, A; Zhang, Y; Zheng, H	1
Akise, Y; Endo, J; Itabashi, Y; Kageyama, T; Mitamura, H; Murata, M; Nagatomo, Y; Nakajima, Y; Tsugu, T	1
Cheng, WY; Drea, E; Duh, MS; Gauthier-Loiselle, M; Miao, R; Oh, WK; Szatrowski, TP; Vekeman, F	1
Basso, U; Caffo, O; Campadelli, E; Conteduca, V; De Giorgi, U; Facchini, G; Fratino, L; Gasparro, D; Kinspergher, S; Maines, F; Massari, F; Messina, C; Mosillo, C; Procopio, G; Rossetti, S; Sabbatini, R; Sava, T; Scagliarini, S; Sirotova, S; Veccia, A; Verzoni, E	1
Barata, PC; Edwin, NC; Emamekhoo, H; Garcia, JA; Grivas, P; Woo, KM	1
Arai, S; Balk, SP; Bhasin, M; Bhasin, SS; Calagua, C; Corey, E; Gao, C; Montgomery, B; Mostaghel, EA; Nelson, PS; Russo, JW; Taplin, ME; Voznesensky, OS; Ye, H	1
Brown, JS; Cunningham, JJ; Gatenby, RA; Staňková, K	1
Eto, M; Inokuchi, J; Kobayashi, T; Namitome, R; Shiota, M; Tatsugami, K	1
Carles, J; Gillessen, S; Heidenreich, A; Heinrich, D; Keizman, D; Miller, K; Nilsson, S; O'Sullivan, JM; Reeves, J; Saad, F; Seger, M; Wirth, M	1
Alsinnawi, M; Balk, S; Bianchi-Frias, D; Burns, J; Cho, E; Montgomery, RB; Mostaghel, EA; Nelson, PS; Porter, C; Slee, AE; Sowalsky, A; Taplin, ME; True, L; Ye, H; Zhang, A; Zhang, X	1
Barbosa, FG; Buchpiguel, CA; Costa, LB; Dzik, C; Marin, JFG; Nunes, RF; Queiroz, MA	1
Allan, AL; Annala, M; Basappa, NS; Beja, K; Chi, KN; Eigl, BJ; Ellard, SL; Finch, D; Gregg, RW; Hotte, SJ; Joshua, AM; Kollmannsberger, C; Macfarlane, RJ; North, S; Powers, J; Ruether, JD; Salim, M; Seymour, L; Tinker, A; Torri, V; Tu, D; Winquist, EW; Wyatt, AW	1
Dubinsky, S; Emmenegger, U; McFarlane, TRJ; McLeod, AG; Thawer, A	1
Hashimoto, J; Hashimoto, K; Hotta, H; Inoue, R; Kunishima, Y; Masumori, N; Muranaka, T; Shindo, T; Tabata, H; Takahashi, A; Tanaka, T; Yanase, M	1
Dorff, TB; Goldkorn, A; Groshen, S; Gross, ME; Kuhn, P; Pinski, JK; Quinn, DI; Sadeghi, S; Tsao-Wei, D	1
Atenafu, E; Duong, BTV; Green, BJ; Hansen, AR; Joshua, AM; Kelley, SO; Labib, M; Mohamadi, RM; Nguyen, V; Thiagalingam, P; Weeber, P	1
Gennigens, C; Sautois, B	1
Boegemann, M; Cronauer, MV; Hajili, T; Herrmann, E; Jentzmik, F; Krabbe, LM; Ohlmann, CH; Schnoeller, TJ; Schrader, AJ; Schrader, M; Stoeckle, M	1
Attard, G; Bianchini, D; de Bono, JS; Dearnaley, D; Ferraldeschi, R; Lorente, D; Mukherji, D; Omlin, A; Parker, C; Pezaro, CJ; Sandhu, S; Van As, N; Zaidi, S	1
Gallego, IG; Garcia-Carbonero, R; Giménez, EV; Giuliani, R; Gravanis, I; Hemmings, RJ; Jiménez, JC; Lopez, AS; O'Connor, D; Pignatti, F; Salmonson, T	1
Altavilla, A; Attard, G; Bianchini, D; de Bono, JS; Dearnaley, D; Ferraldeschi, R; Lorente, D; Omlin, AG; Parker, C; Pezaro, CJ	1
Antonarakis, ES; Bassi, S; Carducci, MA; Eisenberger, MA; Schweizer, MT; Wang, H; Zhou, XC	1
Li, B; Liu, SX; Xia, J; Zhang, TS; Zhou, ZR	1
Lin, DW; Mostaghel, EA	1
Albers, P; Eichenauer, R; Geiges, G; Grimm, MO; König, F; Mickisch, G; Miller, K; Pfister, D; Schwentner, C; Suttmann, H; Zastrow, S	1
Antonarakis, ES; Luo, J; Nakazawa, M	1
Antonarakis, ES; Luber, B; Nadal, R; Schweizer, MT; Suzman, DL	1
Byun, SS; Hong, SJ; Kheoh, T; Kim, CS; Kwak, C; Lee, HM; Ou, YC; Rhim, HY; Wan, Y; Wu, HC; Wu, TT; Yeh, H; Yu, MK	1
Boegemann, M; Brasso, K; de Bono, J; Lorente, D; Merseburger, AS; Retz, M; Schmid, SC; Schrader, AJ; Thomsen, FB; von Klot, CA	1
Castellano, D; Daugaard, G; De Porre, P; Galli, L; Garrido, JM; Géczi, L; George, DJ; Goon, B; Hotte, SJ; Lee, E; Londhe, A; Mainwaring, PN; McGowan, T; Molina, A; Naini, V; Saad, F; Souza, C; Sternberg, CN; Tay, MH; Todd, MB	1
Evans, CP; Isaacs, WB; Karantanos, T; Montironi, R; Thompson, TC; Tombal, B	1
Ardiani, A; Donahue, RN; Gameiro, SR; Hodge, JW; Kwilas, AR	1
Auchus, RJ; Mundle, SD; Nguyen, S; Yu, MK	1
Carles, J; de Bono, JS; De Porre, P; de Souza, P; Fizazi, K; Flaig, TW; Griffin, TW; Higano, CS; Kheoh, T; Li, J; Logothetis, CJ; Miller, K; Molina, A; Mulders, PF; Naini, V; Park, YC; Rathkopf, DE; Ryan, CJ; Saad, F; Shore, ND; Small, EJ; Smith, MR; Sternberg, CN; Taplin, ME; Yu, MK	1
Armstrong, AJ; Chin, B; Dhawan, MS; George, DJ; Harrison, MR; Healy, P; Oldan, J; Zhang, T	1
Attard, G; Bianchini, D; Crespo, M; de Bono, JS; Ferraldeschi, R; Figueiredo, I; Flohr, P; Lorente, D; Miranda, S; Nowakowska, K; Riisnaes, R; Rodrigues, DN; Sideris, S; Terstappen, LW; van Dalum, G; Zafeiriou, Z	1
Berlin, A; Fernández, MI	1
Fenner, A	1
Caffo, O; Chiuri, VE; Conteduca, V; De Giorgi, U; Derosa, L; Fratino, L; Maines, F; Petracci, E; Santini, D; Santoni, M; Testoni, S; Veccia, A	1
He, L; Li, L; Long, Z	1
Crawford, ED; Higano, CS; Hussain, M; Petrylak, DP; Shore, ND	1
Benoist, GE; Gerritsen, WR; Kramers, C; Mulders, PF; Schers, HJ; van Erp, PH; Westdorp, H	1
Bria, E; Caffo, O; Galligioni, E; Maines, F; Tortora, G; Trentin, C; Veccia, A	1
Wadman, M	1
Rexer, H	1
Divine, GW; Hafron, JM; Hung, J; Hwang, C; Taylor, AR	1
Abazeed, M; Alyamani, M; Auchus, RJ; Balk, SP; Li, J; Li, Z; Rogacki, K; Sharifi, N; Taplin, ME; Upadhyay, SK	1
Antoun, J; Bteich, F; Ghosn, M; Jalkh, A; Kourie, HR	1
Azoitei, A; Cronauer, MV; Godau, B; Hoda, MR; Merseburger, AS; Schmid, E	1
Balk, SP; Bhasin, M; Bubley, GJ; Domachevsky, L; Kantoff, PW; Lis, R; Marck, BT; Matsumoto, AM; McKay, RR; Montgomery, B; Mostaghel, EA; Taplin, ME; Voznesensky, O; Werner, L; Zhang, Z; Zukotynski, KA	1
Balea-Filgueiras, J; Martín-Herranz, I; Ramudo-Cela, L; Vizoso-Hermida, JR	1
Albiges, L; Attard, G; Bianchini, D; de Bono, J; Fizazi, K; Loriot, Y; Massard, C; Mateo, J; Mehra, N; Petrylak, DP; Pezaro, C; Ryan, CJ; Shen, L; Varga, A	1
Concepcion, RS; Crawford, ED; Finkelstein, SE; Gomella, LG; Keane, TE; Koo, PJ; O'Sullivan, JM; Petrylak, DP; Saad, F; Shore, N; Sieber, P; Slovin, SF; Stone, NN; Tombal, B; Vogelzang, NJ; Yu, EY	1
Klein, EA; Raghavan, D	1
Attard, G; Barrett, M; Clark, J; Cooper, CS; de Bono, JS; Dearnaley, D; Dowsett, M; Folkerd, E; Kaye, SB; Lee, G; Martins, V; Parker, C; Raynaud, F; Reid, AH; Settatree, S; Yap, TA	1
Ryan, CJ; Van Allen, EM	1
A'Hern, R; Attard, G; de Bono, JS; Dearnaley, D; Dowsett, M; Folkerd, E; Kaye, SB; Kheoh, T; Lee, G; Maier, G; Messiou, C; Molife, LR; Molina, A; Olmos, D; Oommen, NB; Parker, C; Reid, AH; Sinha, R; Thompson, E	1
Attard, G; Cooper, CS; de Bono, JS	1
Raghavan, D; Shepard, DR	1
Anand, A; Bubley, GJ; Danila, DC; de Bono, JS; Denmeade, SR; Fleisher, M; Haqq, C; Kheoh, T; Koscuiszka, M; Larson, SM; Molina, A; Morris, MJ; Ryan, CJ; Scher, HI; Schwartz, LH; Smith, MR; Taplin, ME	1
Hara, T; Kusaka, M; Yamaoka, M	1
Alhasso, A; Ansari, A; Ansari, J; Glaholm, J; Hussain, SA; Mahmood, R	1
Bianchini, D; Cheng, T; Chi, KN; Chieffo, N; Chu, L; de Bono, JS; Efstathiou, E; Ellard, SL; Fizazi, K; Flaig, TW; Fléchon, A; Goodman, OB; Hainsworth, JD; Haqq, CM; Harland, S; Hutson, TE; Jones, RJ; Kheoh, T; Logothetis, CJ; Loriot, Y; Mainwaring, P; Molina, A; North, S; Patterson, H; Ryan, CJ; Saad, F; Saleh, M; Scher, HI; Scholz, M; Staffurth, JN; Sternberg, CN; Zivi, A	1
Sonpavde, G	1
Arlt, W; Attard, G; Auchus, RJ; Cassidy, AM; de Bono, JS; Dowsett, M; Folkerd, E; Hughes, BA; Oommen, NB; Reid, AH; Thompson, E	1
Gschwend, JE; Heck, MM; Höppner, M; Horn, T; Retz, M; Thalgott, M	1
Herchenhorn, D; Maluf, FC; Smaletz, O	1
Attard, G; Baikady, B; Bianchini, D; de Bono, J; Hunt, J; Maier, G; Mezynski, J; Mulick Cassidy, A; Olmos, D; Pezaro, C; Reid, AHM; Sandhu, S; Sarvadikar, A; Sheridan, E; Thompson, E; Zivi, A	1
Kuczyk, MA; Merseburger, AS; Wolff, JM	1
Cheng, ML; Ryan, CJ	1

Reviews

24 review(s) available for abiraterone and Disease Exacerbation

Article	Year
Efficacy and safety of bipolar androgen therapy in mCRPC after progression on abiraterone or enzalutamide: A systematic review. Urologic oncology, 2022, Volume: 40, Issue:1 Topics: Androgens; Androstenes; Benzamides; Disease Progression; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Testosterone; Treatment Outcome	2022
Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients. Clinical drug investigation, 2020, Volume: 40, Issue:3 Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Male; Neoplasm Grading; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic	2020
Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis. Prostate cancer and prostatic diseases, 2020, Volume: 23, Issue:4 Topics: Androgen Antagonists; Androstenes; Benzamides; Clinical Trials, Phase II as Topic; Disease Progression; Drug Administration Schedule; Humans; Kallikreins; Male; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome	2020
Abiraterone-induced rhabdomyolysis resulting in acute kidney injury: A case report and review of the literature. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2018, Volume: 24, Issue:4 Topics: Acute Kidney Injury; Aged; Androstenes; Disease Progression; Fatal Outcome; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Rhabdomyolysis	2018
Management of anticoagulation in patients with metastatic castration-resistant prostate cancer receiving abiraterone + prednisone. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2019, Volume: 27, Issue:9 Topics: Androstenes; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Interactions; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Retrospective Studies; Thrombosis; Treatment Outcome	2019
Abiraterone for treatment of metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:3 Topics: Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Humans; Kallikreins; Male; Placebos; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant	2014
Practical guide to the use of abiraterone in castration resistant prostate cancer. The Canadian journal of urology, 2014, Volume: 21, Issue:2 Supp 1 Topics: Androgens; Androstenes; Androstenols; Antineoplastic Agents; Disease Progression; Humans; Male; Practice Guidelines as Topic; Prostatic Neoplasms, Castration-Resistant; Testosterone; Treatment Outcome	2014
[Metastatic castration-resistant prostate cancer: position paper for structured therapy monitoring]. Der Urologe. Ausg. A, 2014, Volume: 53, Issue:5 Topics: Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Taxoids	2014
Androgen receptor splice variants in the era of enzalutamide and abiraterone. Hormones & cancer, 2014, Volume: 5, Issue:5 Topics: Alternative Splicing; Androstenes; Animals; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen	2014
Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. European urology, 2015, Volume: 67, Issue:3 Topics: Androgen Antagonists; Androstenes; Animals; Antineoplastic Agents, Hormonal; Benzamides; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Signal Transduction; Thiohydantoins	2015
Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer. The oncologist, 2014, Volume: 19, Issue:12 Topics: Androstenes; Antineoplastic Agents, Hormonal; Disease Progression; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant	2014
[Advances in the treatment of castration-resistant prostate cancer: emphasis in new hormonal therapies]. Revista medica de Chile, 2015, Volume: 143, Issue:2 Topics: Androstenes; Antineoplastic Agents, Hormonal; Benzamides; Biomarkers, Tumor; Disease Progression; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids	2015
Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies. The Journal of urology, 2015, Volume: 194, Issue:6 Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Disease Progression; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Survival Rate; Taxoids; Tissue Extracts	2015
[Hormone therapy in prostate cancer; a pharmacotherapeutic challenge]. Nederlands tijdschrift voor geneeskunde, 2015, Volume: 159 Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Benzamides; Disease Progression; Humans; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Testosterone; Treatment Outcome	2015
Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer. Critical reviews in oncology/hematology, 2015, Volume: 96, Issue:3 Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids	2015
C-terminally truncated constitutively active androgen receptor variants and their biologic and clinical significance in castration-resistant prostate cancer. The Journal of steroid biochemistry and molecular biology, 2017, Volume: 166 Topics: Alternative Splicing; Androgens; Androstenes; Androstenols; Animals; Benzamides; Biomarkers, Tumor; Codon, Terminator; Disease Progression; Epithelial-Mesenchymal Transition; Genetic Variation; Genome, Human; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Protein Domains; Signal Transduction; Thiohydantoins; Transcription Factors	2017
The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II). Urology, 2017, Volume: 104 Topics: Androgens; Androstenes; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Disease Progression; Humans; Immunotherapy; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Phenylthiohydantoin; Practice Guidelines as Topic; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Treatment Outcome	2017
Novel secondary hormonal therapy in advanced prostate cancer: an update. Current opinion in urology, 2009, Volume: 19, Issue:3 Topics: Androgen Antagonists; Androstenes; Androstenols; Disease Progression; Humans; Ketoconazole; Male; Prostatic Neoplasms; Receptors, Androgen	2009
Innovations in the systemic therapy of prostate cancer. Nature reviews. Clinical oncology, 2010, Volume: 7, Issue:1 Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Disease Progression; Drug Delivery Systems; Drugs, Investigational; Humans; Male; Multicenter Studies as Topic; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Osteoporosis; Prostatectomy; Prostatic Neoplasms; Salvage Therapy; Survival Analysis	2010
Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Sep-01, Volume: 16, Issue:17 Topics: Androgens; Androstenes; Androstenols; Disease Progression; Humans; Male; Orchiectomy; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Steroid 17-alpha-Hydroxylase	2010
Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer- current strategies and future directions. Anti-cancer agents in medicinal chemistry, 2011, Volume: 11, Issue:3 Topics: Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Forecasting; Humans; Male; Mitoxantrone; Neoplasm Metastasis; Prednisolone; Prostatic Neoplasms; Quality of Life; Taxoids; Treatment Failure	2011
Castration-resistant prostate cancer: systemic therapy in 2012. Clinics (Sao Paulo, Brazil), 2012, Volume: 67, Issue:4 Topics: Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Clinical Trials as Topic; Disease Progression; Docetaxel; Evidence-Based Medicine; Humans; Male; Orchiectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts	2012
[Pathophysiology and therapy of castration-resistant prostate cancer]. Der Urologe. Ausg. A, 2013, Volume: 52, Issue:2 Topics: Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Benzamides; Biomarkers, Tumor; Disease Progression; Drug Resistance, Neoplasm; Humans; Imidazoles; Male; Naphthalenes; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms	2013
Abiraterone acetate for the treatment of prostate cancer. Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:1 Topics: Adenocarcinoma; Administration, Oral; Androstenes; Androstenols; Antineoplastic Agents; Castration; Disease Progression; Humans; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Receptors, Androgen	2013

Trials

23 trial(s) available for abiraterone and Disease Exacerbation

Article	Year
Rucaparib or Physician's Choice in Metastatic Prostate Cancer. The New England journal of medicine, 2023, 02-23, Volume: 388, Issue:8 Topics: Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Genes, BRCA1; Genes, BRCA2; Humans; Indoles; Male; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant	2023
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. Annals of oncology : official journal of the European Society for Medical Oncology, 2017, Jul-01, Volume: 28, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents, Hormonal; Benzamides; Biomarkers, Tumor; Circulating Tumor DNA; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; Europe; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiplex Polymerase Chain Reaction; Multivariate Analysis; Mutation; Nitriles; Odds Ratio; Patient Selection; Phenylthiohydantoin; Precision Medicine; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Risk Factors; Time Factors; Treatment Outcome	2017
Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial. BMC cancer, 2017, Oct-10, Volume: 17, Issue:1 Topics: Adult; Aged; Androstenes; Benzamides; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids	2017
Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer. Nature communications, 2017, 11-28, Volume: 8, Issue:1 Topics: Androgens; Androstenes; Disease Progression; Humans; Male; Models, Theoretical; Neoplasm Metastasis; Pilot Projects; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Steroid 17-alpha-Hydroxylase; Testosterone; Time Factors; Treatment Failure; Treatment Outcome	2017
Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts. Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 07-01, Volume: 29, Issue:7 Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; Follow-Up Studies; Humans; Male; Neoplasm Metastasis; Neoplastic Cells, Circulating; Prednisone; Prognosis; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Survival Rate	2018
Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol. BMJ open, 2018, 05-14, Volume: 8, Issue:5 Topics: Androgen Antagonists; Androstenes; Benzamides; Clinical Trials, Phase III as Topic; Disease Progression; Exercise Therapy; Humans; Male; Multicenter Studies as Topic; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Androgen; United States	2018
Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study). British journal of cancer, 2018, Volume: 119, Issue:9 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents, Hormonal; Dexamethasone; Disease Progression; Humans; Male; Middle Aged; Oncogene Proteins, Fusion; Pilot Projects; Prednisone; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; PTEN Phosphohydrolase; Receptors, Androgen; Survival Analysis; Treatment Outcome	2018
Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program. Future oncology (London, England), 2018, Volume: 14, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Italy; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies	2018
Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program. BMC cancer, 2019, Jan-07, Volume: 19, Issue:1 Topics: Aged; Aged, 80 and over; Androstenes; Bone Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Treatment Outcome	2019
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205. Clinical genitourinary cancer, 2019, Volume: 17, Issue:3 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Canada; Disease Progression; Gonanes; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Prostatic Neoplasms, Castration-Resistant; PTEN Phosphohydrolase; Survival Analysis; Treatment Outcome	2019
Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC). Clinical genitourinary cancer, 2019, Volume: 17, Issue:4 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Humans; Male; Middle Aged; Neoplastic Cells, Circulating; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Treatment Outcome	2019
Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: a phase II bridging study in Korean and Taiwanese patients. International journal of urology : official journal of the Japanese Urological Association, 2014, Volume: 21, Issue:12 Topics: Aged; Androgens; Androstenes; Antineoplastic Agents; Disease Progression; Docetaxel; Drug Therapy, Combination; Glucocorticoids; Humans; Incidence; Male; Orchiectomy; Prednisolone; Prostatic Neoplasms, Castration-Resistant; Republic of Korea; Survival Rate; Taiwan; Taxoids; Treatment Failure	2014
Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. The Lancet. Oncology, 2014, Volume: 15, Issue:11 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Androstenols; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prednisolone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Treatment Outcome	2014
[Recruiting participants - study of therapy of CRPC]. Aktuelle Urologie, 2014, Volume: 45, Issue:5 Topics: Adenocarcinoma; Androgen Antagonists; Androstenes; Biomarkers, Tumor; Disease Progression; Drug Therapy, Combination; Germany; Gonadotropin-Releasing Hormone; Humans; Male; Patient Selection; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant	2014
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study The Lancet. Oncology, 2015, Volume: 16, Issue:2 Topics: Aged; Androstenes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progression; Double-Blind Method; Follow-Up Studies; Humans; Male; Neoplasm Staging; Prednisone; Prognosis; Prostatic Neoplasms, Castration-Resistant; Survival Rate	2015
A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, Feb-15, Volume: 23, Issue:4 Topics: Aged; Androgens; Androstenes; Disease Progression; Drug Resistance, Neoplasm; Dutasteride; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radiography; Receptors, Androgen	2017
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone. Annals of oncology : official journal of the European Society for Medical Oncology, 2017, 01-01, Volume: 28, Issue:1 Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome	2017
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Oct-01, Volume: 26, Issue:28 Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Androstenes; Androstenols; Castration; Disease Progression; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prospective Studies; Prostatic Neoplasms; Treatment Outcome	2008
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Aug-10, Volume: 27, Issue:23 Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Testosterone	2009
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Mar-20, Volume: 28, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Glucocorticoids; Humans; Hyperaldosteronism; Male; Middle Aged; Neoplastic Cells, Circulating; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome	2010
Abiraterone and increased survival in metastatic prostate cancer. The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21 Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Double-Blind Method; Fatigue; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Survival Analysis; Treatment Outcome	2011
Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. The Journal of clinical endocrinology and metabolism, 2012, Volume: 97, Issue:2 Topics: Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Pharmacological; Carcinoma; Chemotherapy, Adjuvant; Disease Progression; Enzyme Inhibitors; Glucocorticoids; Humans; Male; Models, Biological; Orchiectomy; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Treatment Outcome	2012
Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:11 Topics: Aged; Aged, 80 and over; Androgen Receptor Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Disease Progression; Docetaxel; Drug Interactions; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Taxoids; Testosterone	2012

Other Studies

49 other study(ies) available for abiraterone and Disease Exacerbation

Article	Year
New Antiandrogen Compounds Compared to Docetaxel for Metastatic Hormone Sensitive Prostate Cancer: Results from a Network Meta-Analysis. The Journal of urology, 2020, Volume: 203, Issue:4 Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Disease Progression; Docetaxel; Humans; Male; Network Meta-Analysis; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Standard of Care; Thiohydantoins	2020
Radiotherapy in metastatic castration resistant prostate cancer patients with oligo-progression during abiraterone-enzalutamide treatment: a mono-institutional experience. Radiation oncology (London, England), 2019, Nov-14, Volume: 14, Issue:1 Topics: Aged; Aged, 80 and over; Androgen Receptor Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiosurgery; Radiotherapy, Conformal; Receptors, Androgen; Retrospective Studies; Treatment Outcome	2019
TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate Cancer. Clinical genitourinary cancer, 2020, Volume: 18, Issue:2 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Circulating Tumor DNA; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; Gain of Function Mutation; Humans; Liquid Biopsy; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prognosis; Prostate; Prostatic Neoplasms, Castration-Resistant; Tumor Suppressor Protein p53	2020
Adding carboplatin to chemotherapy regimens for metastatic castrate-resistant prostate cancer in postsecond generation hormone therapy setting: Impact on treatment response and survival outcomes. The Prostate, 2020, Volume: 80, Issue:14 Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carboplatin; Disease Progression; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids; Treatment Failure	2020
Challenges of Treating a Patient With Advanced Prostate Cancer During the COVID-19 Pandemic. Oncology (Williston Park, N.Y.), 2020, 08-12, Volume: 34, Issue:8 Topics: Aged; Androgen Antagonists; Androstenes; Anticoagulants; Antineoplastic Agents; Betacoronavirus; Bone Density Conservation Agents; Bone Neoplasms; Cancer Pain; Coronavirus Infections; COVID-19; Disease Progression; Docetaxel; Drug Combinations; Eligibility Determination; Heparin, Low-Molecular-Weight; Humans; Intensive Care Units; Lopinavir; Male; Oxygen Inhalation Therapy; Palliative Care; Pandemics; Pneumonia, Viral; Prostatic Neoplasms, Castration-Resistant; Renal Insufficiency; Respiratory Insufficiency; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; SARS-CoV-2; Severity of Illness Index; Zoledronic Acid	2020
YB-1 variant and androgen receptor axis-targeted agents in metastatic castration-resistant prostate cancer patients. Pharmacogenomics, 2020, Volume: 21, Issue:13 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Cohort Studies; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Genotype; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Y-Box-Binding Protein 1	2020
The clinical benefit of sequential therapy with androgen receptor axis-targeted agents alone in patients with castration-resistant prostate cancer: A propensity score-matched comparison study. The Prostate, 2020, Volume: 80, Issue:15 Topics: Aged; Aged, 80 and over; Androgen Receptor Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Benzamides; Disease Progression; Drug Therapy, Combination; Humans; Male; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Propensity Score; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Treatment Outcome	2020
Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naïve castration-resistant prostate cancer: The Kyoto-Baltimore collaboration. International journal of urology : official journal of the Japanese Urological Association, 2017, Volume: 24, Issue:6 Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Baltimore; Benzamides; Disease Progression; Drug Administration Schedule; Humans; International Cooperation; Japan; Kallikreins; Male; Neoplasm Grading; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Analysis; Time Factors	2017
Lactate dehydrogenase predicts combined progression-free survival after sequential therapy with abiraterone and enzalutamide for patients with castration-resistant prostate cancer. The Prostate, 2017, Volume: 77, Issue:10 Topics: Aged; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Disease-Free Survival; Drug Monitoring; Drug Resistance, Neoplasm; Humans; Japan; L-Lactate Dehydrogenase; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Predictive Value of Tests; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies	2017
Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey. European urology focus, 2018, Volume: 4, Issue:2 Topics: Androstenes; Biomarkers, Tumor; Clinical Decision-Making; Disease Progression; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplastic Cells, Circulating; Practice Patterns, Physicians'; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Surveys and Questionnaires; Taxoids; Treatment Outcome; Tubulin Modulators	2018
Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer. Nucleic acids research, 2018, 02-28, Volume: 46, Issue:4 Topics: Androstenes; Animals; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Chromatin; Disease Progression; Drug Resistance, Neoplasm; Epigenesis, Genetic; Genomics; Humans; Male; Mice, SCID; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; rap GTP-Binding Proteins; Receptors, Androgen; RNA Splicing	2018
Prognostic and Therapeutic Implications of Circulating Androgen Receptor Gene Copy Number in Prostate Cancer Patients Using Droplet Digital Polymerase Chain Reaction. Clinical genitourinary cancer, 2018, Volume: 16, Issue:3 Topics: Aged; Androstenes; Benzamides; Bridged-Ring Compounds; Disease Progression; Disease-Free Survival; DNA, Neoplasm; Gene Dosage; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Polymerase Chain Reaction; Prognosis; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; Taxoids	2018
Real world evidence: Abiraterone use post-docetaxel in metastatic castrate-resistant prostate cancer. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2019, Volume: 25, Issue:6 Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate	2019
Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer. BJU international, 2019, Volume: 123, Issue:2 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Asymptomatic Diseases; Dexamethasone; Disease Progression; Drug Substitution; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prognosis; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies	2019
Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer. Cancer research, 2018, 10-15, Volume: 78, Issue:20 Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androstenes; Animals; Benzamides; Cell Line, Tumor; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Epigenesis, Genetic; Humans; Male; Mice; Mice, SCID; Neoplasm Recurrence, Local; Neoplasm Transplantation; Nitriles; Oligonucleotides, Antisense; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Signal Transduction	2018
Cancer therapeutics-related cardiac dysfunction in a patient treated with abiraterone for castration-resistant prostate cancer. Journal of medical ultrasonics (2001), 2019, Volume: 46, Issue:2 Topics: Aged, 80 and over; Androstenes; Antineoplastic Agents; Disease Progression; Drug Substitution; Heart Failure; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2019
Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncolo Urologic oncology, 2018, Volume: 36, Issue:11 Topics: Aged; Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome	2018
Evaluation of Response to Enzalutamide Consecutively After Abiraterone Acetate/Prednisone Failure in Patients With Metastatic Castration-resistant Prostate Cancer. Clinical genitourinary cancer, 2018, Volume: 16, Issue:6 Topics: Abiraterone Acetate; Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prednisone; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Time Factors; Treatment Failure; Treatment Outcome	2018
Downregulation of Cancer research, 2018, 11-15, Volume: 78, Issue:22 Topics: Alternative Splicing; Androgen Antagonists; Androstenes; Animals; Benzamides; Cell Line, Tumor; Dipeptidyl Peptidase 4; Disease Progression; Down-Regulation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gene Expression Profiling; Humans; Male; Mice; Mice, SCID; Neoplasm Recurrence, Local; Neoplasm Transplantation; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; RNA, Small Interfering; Signal Transduction; Sitagliptin Phosphate	2018
Optimal control to develop therapeutic strategies for metastatic castrate resistant prostate cancer. Journal of theoretical biology, 2018, 12-14, Volume: 459 Topics: Androstenes; Disease Management; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance; Game Theory; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Quality of Life	2018
Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with de novo metastatic prostate cancer. International journal of urology : official journal of the Japanese Urological Association, 2019, Volume: 26, Issue:3 Topics: Aged; Androgen Antagonists; Androstenes; Antineoplastic Agents; Biopsy, Large-Core Needle; Clinical Trials as Topic; Disease Progression; Docetaxel; Humans; Japan; Male; Neoplasm Recurrence, Local; Orchiectomy; Prognosis; Progression-Free Survival; Prostate; Prostatic Neoplasms; Retrospective Studies; Risk Assessment	2019
Association of prostate cancer SLCO gene expression with Gleason grade and alterations following androgen deprivation therapy. Prostate cancer and prostatic diseases, 2019, Volume: 22, Issue:4 Topics: Adult; Aged; Androgen Antagonists; Androstenes; Dehydroepiandrosterone Sulfate; Disease Progression; Docetaxel; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Grading; Organic Anion Transporters; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Solute Carrier Organic Anion Transporter Family Member 1B3; Testosterone; Treatment Outcome	2019
Pseudoprogression on PSMA PET imaging of a mCRPC patient under anti-PD1 treatment. European journal of nuclear medicine and molecular imaging, 2019, Volume: 46, Issue:7 Topics: Aged, 80 and over; Androstenes; Anilides; Antibodies, Monoclonal, Humanized; Antigens, Surface; Brachytherapy; Disease Progression; Gallium Radioisotopes; Gene Expression Regulation, Neoplastic; Glutamate Carboxypeptidase II; Goserelin; Humans; Ligands; Male; Nitriles; Positron-Emission Tomography; Programmed Cell Death 1 Receptor; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Salvage Therapy; Tosyl Compounds	2019
Serum testosterone level is a useful biomarker for determining the optimal treatment for castration-resistant prostate cancer. Urologic oncology, 2019, Volume: 37, Issue:7 Topics: Aged; Androgen Antagonists; Androstenes; Benzamides; Biomarkers, Tumor; Clinical Decision-Making; Disease Progression; Drug Resistance, Neoplasm; Feasibility Studies; Follow-Up Studies; Humans; Kallikreins; Male; Neoplasm Grading; Nitriles; Patient Selection; Phenylthiohydantoin; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Testosterone; Time Factors	2019
Phenotypic Profiling of Circulating Tumor Cells in Metastatic Prostate Cancer Patients Using Nanoparticle-Mediated Ranking. Analytical chemistry, 2019, 08-06, Volume: 91, Issue:15 Topics: Androstenes; Antineoplastic Agents, Immunological; Benzamides; Cadherins; Disease Progression; Epithelial Cell Adhesion Molecule; Humans; Magnetite Nanoparticles; Male; Neoplastic Cells, Circulating; Nitriles; Phenotype; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen	2019
[New treatments for castration-resistant prostate cancer]. Revue medicale de Liege, 2013, Volume: 68, Issue:2 Topics: Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Male; Multicenter Studies as Topic; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome	2013
Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. European urology, 2014, Volume: 65, Issue:1 Topics: Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Failure	2014
Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer. British journal of cancer, 2013, Sep-03, Volume: 109, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Diethylstilbestrol; Disease Progression; Docetaxel; Estrogens, Non-Steroidal; Humans; Male; Middle Aged; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Taxoids; Treatment Outcome	2013
The European medicines agency review of abiraterone for the treatment of metastatic castration-resistant prostate cancer in adult men after docetaxel chemotherapy and in chemotherapy-naive disease: summary of the scientific assessment of the committee for The oncologist, 2013, Volume: 18, Issue:9 Topics: Adult; Androstenes; Androstenols; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Drug Approval; European Union; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome	2013
Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. European urology, 2014, Volume: 66, Issue:3 Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retreatment; Retrospective Studies; Survival Rate; Taxoids; Treatment Failure	2014
The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer. European urology, 2014, Volume: 66, Issue:4 Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cohort Studies; Disease Progression; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Assessment; Survival Rate; Taxoids; Treatment Outcome	2014
Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone. The Prostate, 2014, Volume: 74, Issue:13 Topics: Adenocarcinoma; Aged; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Bone Neoplasms; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome	2014
Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis. European urology, 2015, Volume: 68, Issue:2 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Compassionate Use Trials; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Drug Substitution; Europe; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Risk Factors; Taxoids; Time Factors; Treatment Outcome	2015
Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway. Oncotarget, 2014, Oct-15, Volume: 5, Issue:19 Topics: Androgen Antagonists; Androstenes; Animals; Apoptosis; Benzamides; Cell Line, Tumor; Disease Progression; Humans; Immunomodulation; Immunotherapy; Male; Mice; Neuronal Apoptosis-Inhibitory Protein; Nitriles; Phenylthiohydantoin; Prostate; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; RNA Interference; RNA, Small Interfering; T-Lymphocytes	2014
Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer. Clinical genitourinary cancer, 2015, Volume: 13, Issue:4 Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiography; Retrospective Studies; Taxoids; Treatment Outcome	2015
Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents. British journal of cancer, 2015, Mar-31, Volume: 112, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Androstenes; Benzamides; Cell Line, Tumor; Disease Progression; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen	2015
Prostate cancer: PSA kinetics predict survival in patients treated with abiraterone. Nature reviews. Urology, 2015, Volume: 12, Issue:5 Topics: Androstenes; Biomarkers, Tumor; Disease Progression; Global Health; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate	2015
Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone. The Prostate, 2015, Volume: 75, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Androstenes; Disease Progression; Disease-Free Survival; Enzyme Inhibitors; Humans; Male; Metabolic Syndrome; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Factors; Steroid 17-alpha-Hydroxylase; Survival Rate; Treatment Outcome	2015
[A case of metastatic castration-resistant prostate cancer by abiraterone treatment]. Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2015, Volume: 40, Issue:6 Topics: Androstenes; Bone Neoplasms; Disease Progression; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant	2015
Treatment: When less is more. Nature, 2015, Dec-17, Volume: 528, Issue:7582 Topics: Androstenes; Benzamides; Castration; Clinical Trials as Topic; Disease Progression; Humans; Male; Neoplasm Metastasis; Nitriles; Patient Selection; Phenylthiohydantoin; Precision Medicine; Prognosis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Testosterone	2015
[Not Available]. Aktuelle Urologie, 2016, Volume: 47, Issue:2 Topics: Administration, Oral; Adult; Aged; Androstenes; Disease Progression; Drug Approval; Follow-Up Studies; Germany; Humans; Male; Medication Adherence; Middle Aged; Physician-Patient Relations; Prostatic Neoplasms, Castration-Resistant	2016
The Effect of Time to Castration Resistance on Outcomes With Abiraterone and Enzalutamide in Metastatic Prostate Cancer. Clinical genitourinary cancer, 2016, Volume: 14, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Benzamides; Disease Progression; Disease-Free Survival; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Regression Analysis; Survival Analysis; Treatment Outcome	2016
Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy. Nature, 2016, 05-26, Volume: 533, Issue:7604 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Abiraterone Acetate; Administration, Oral; Androgen Antagonists; Androgens; Androstenes; Animals; Cell Line, Tumor; Disease Progression; Dutasteride; Humans; Male; Mice; Oxidation-Reduction; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Xenograft Model Antitumor Assays	2016
Bilateral Choroidal Metastases from Prostate Cancer revealed in a patient under Abiraterone - Fourteen years after diagnosis. The Gulf journal of oncology, 2016, Volume: 1, Issue:21 Topics: Androstenes; Antineoplastic Agents; Disease Progression; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2016
Study of cases of abiraterone discontinuation due to toxicity in pre-chemotherapy after 1 year's experience. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2017, Volume: 23, Issue:8 Topics: Abiraterone Acetate; Aged, 80 and over; Androstenes; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Safety-Based Drug Withdrawals; Taxoids; Time Factors; Treatment Outcome	2017
Prostate cancer: moving forward by reinventing the wheel...but this time it is round. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Oct-01, Volume: 26, Issue:28 Topics: Androstenes; Androstenols; Castration; Clinical Trials as Topic; Disease Progression; Humans; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms	2008
Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer cell, 2009, Dec-08, Volume: 16, Issue:6 Topics: Androgens; Androstenes; Androstenols; Benzamides; Disease Progression; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen; Receptors, Estrogen; Signal Transduction	2009
Abiraterone and increased survival in metastatic prostate cancer. The New England journal of medicine, 2011, 08-25, Volume: 365, Issue:8 Topics: Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Taxoids	2011
[Compassionate use of abiraterone and cabazitaxel: first experiences in docetaxel-pretreated castration-resistant prostate cancer patients]. Der Urologe. Ausg. A, 2012, Volume: 51, Issue:3 Topics: Aged; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Compassionate Use Trials; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids	2012